Jubilant Pharmova Ltd (JUBLPHARMA)
₹923.80
Mkt cap
₹14,716 Cr
P/E ratio
37.90
P/B
2.08
Div yield
0.54%
ROE
6.53%
ROCE
8.99%
EPS (TTM)
₹24.37
Book value
₹445
52W range
786–1,183
Sector
Healthcare
Price history
Previous close
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]
NSE JUBLPHARMABSE 530019
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−21.91% from high₹924
₹786+17.52% from low₹1,183
Current
₹923.80
Prev close
₹946.00
Day
−2.35%
Price performance
1D
−2.16%
1W
−1.35%
1M
−11.70%
3M
−3.75%
6M
−0.13%
1Y
−17.88%
YTD
−12.47%
Financials
Revenue, profit & margin
P/E ratio
37.9×
JUBLPHARMA is 11% above the sector median of 34.0×
JUBLPHARMA37.9×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 | |
| Expenses | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 | |
| Operating Profit | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 | |
| OPM % | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% | |
| Other Income | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 | |
| Interest | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 | |
| Depreciation | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 | |
| Profit before tax | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 | |
| Tax % | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% | |
| Net Profit | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 | |
| EPS in Rs | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | 3.55 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
13 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.12% · closed higher next day 23 of last 62
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 2 Feb '24◦ | 30 May '24 | 19 Jul '24◦ | 25 Oct '24◦ | 31 Jan '25◦ | 16 May '25◦ | 29 Jul '25 | 31 Oct '25 | 6 Feb '26 | 22 May '26 | 10 Aug '26◦ |
| Earnings day | −4.05% | −1.79% | +0.79% | −3.37% | +3.60% | +0.37% | +1.53% | −1.81% | −1.56% | −3.72% | −0.52% | +0.24% |
| +1 day | −5.71% | −1.91% | −2.56% | −3.38% | +4.74% | −2.32% | +4.62% | +5.29% | +4.60% | −3.21% | −0.43% | −7.49% |
| +5 days | +0.69% | −1.01% | +2.04% | −3.48% | +16.98% | +2.68% | +18.60% | −4.69% | +1.79% | −6.25% | −2.38% | −10.04% |
| +15 days | +8.12% | −2.68% | +1.98% | +13.59% | +6.80% | −0.72% | +20.97% | −7.67% | −3.75% | −11.04% | −2.01% | −5.72% |
| +30 days | +15.19% | −4.18% | +2.21% | +22.33% | +6.28% | −8.57% | +28.02% | −4.22% | −2.91% | −16.19% | −3.25% | +9.90% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Sep 202647.67%Promoter
Promoters47.67%
FIIs15.37%0.50
DIIs13.01%0.61
Public23.38%0.12
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Jubilant Pharmo | ₹923.80 | 37.92 | 14,716 | 0.54% | 56 | −45.09% | 2,229 | +17.29% | 8.99% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts52
PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026PPTOct 2025TranscriptJul 2025PPTJul 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025PPTJan 2025PPTOct 2024PPTJul 2024PPTMay 2024PPTMay 2024PPTFeb 2024PPTOct 2023PPTJul 2023PPTMay 2023TranscriptFeb 2023TranscriptNov 2022PPTNov 2022TranscriptAug 2022TranscriptJun 2022
Credit ratings6
Announcements5
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026 30 Oct - Board meeting on November 13, 2026 to consider Q2 and half-year FY2027 results.Announcement under Regulation 30 (LODR)-Newspaper Publication 23 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 22 OctShareholder Meeting / Postal Ballot-Notice of Postal Ballot 21 OctAnnouncement under Regulation 30 (LODR)-Credit Rating 21 Oct - India Ratings assigned IND AA+/Stable to proposed ₹1,400 crore NCDs on October 21, 2026.